Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03384563 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 22, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv10
  2. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v9
  3. Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v8
  4. Primary and study completion dates: Dec 31, 2021 to Dec 31, 2023v7
  5. 2 versions Re-verified since Feb 5, 2020, no change to tracked fieldsv5-v6
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 12, 2018 to Feb 18, 2018 · Site details revisedv4 Show 2 more changesShow less
    • Start date changed from estimate of Dec 12, 2018 to Feb 18, 2018
    • Site details revised
  2. Primary and study completion dates: Dec 31, 2019 to Dec 31, 2021 Start date: Jan 1, 2018 to Dec 12, 2018v3 Show 1 more changeShow less
    • Start date: Jan 1, 2018 to Dec 12, 2018
  3. Eligibility criteria shortened, about 9 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.
Trial Details
NCT Number NCT03384563
Lead Sponsor Baylor College of Medicine
Conditions Pediatric Anesthesia
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov